Viewing

AAO

Shorts

Remigromig in DME: Subgroups, duration and what comes next
1:01
Remigromig in DME: Subgroups, duration and what comes next
a month ago
How a subcutaneous option could change thyroid eye disease care
0:55
How a subcutaneous option could change thyroid eye disease care
a month ago
Using videos and recorded visits for IOL counseling
1:23
Using videos and recorded visits for IOL counseling
a month ago
A complementary lens approach to refractive IOL selection
1:02
A complementary lens approach to refractive IOL selection
a month ago
Approaching ocular pain like a detective
1:03
Approaching ocular pain like a detective
a month ago
Safety profile of elegrobart in the REVEAL-1 trial
0:52
Safety profile of elegrobart in the REVEAL-1 trial
a month ago
What the first whole eye transplant in a human revealed
1:11
What the first whole eye transplant in a human revealed
a month ago
How MCO-010 optogenetic therapy works in RP
1:08
How MCO-010 optogenetic therapy works in RP
a month ago
Linus Shen, MD, on making the most of fellowship
0:52
Linus Shen, MD, on making the most of fellowship
a month ago
Soluble IL-2 Receptor Shows Promise for Detecting Ocular Sarcoidosis
0:56
Soluble IL-2 Receptor Shows Promise for Detecting Ocular Sarcoidosis
a month ago

Latest Content

Conference

The company announced updated data from the OPTIC extension study of patients diagnosed with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco. Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden.

Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.